Crucell Terug naar discussie overzicht

Zomaar ff tussendoor

1. flosz 18 augustus 2009 16:21

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Project Number: 272200800056C-0-0-1
   Title: ADVANCED DEVELOPMENT OF MULTIVALENT FILOVIRUS VACCINES
   Organization: CRUCELL HOLLAND, BV
   
   Year 2008
   Funding IC NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
   FY Total Cost by IC $13,496,364
   
   This contract supports advanced development of a of multivalent filovirus (Ebola and Marburg) vaccine through cGMP manufacturing with an option for a Phase 1 clinical trial. Additional options provide for large scale production, development of a lyophilized formulation and a Phase 2 clinical trial.
   projectreporter.nih.gov/project_info_...
   
2. [verwijderd] 26 mei 2010 22:08

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Hier zou Flosz hem volgens mij zetten.
   Thursday, May 20, 2010
   
   Experimental Vaccine Protects Monkeys from New Ebola Virus
   
   New research has found that an experimental Ebola vaccine developed by researchers at the National Institutes of Health protects monkeys against not only the two most lethal Ebola virus species for which it was originally designed, both recognized in 1976, but also against a newer Ebola virus species that was identified in 2007.
   
   Nancy J. Sullivan, Ph.D., of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID), NIH, led the study team, which included collaborators from the U.S. Army Medical
   Transmission electron micrograph of Ebola virus
   View larger image
   Credit: CDC
   Research Institute of Infectious Diseases in Fort Detrick, Md, and the Centers for Disease Control and Prevention in Atlanta. Their findings appear May 20 in the open-access journal PLoS Pathogens. Currently, there are no specific treatments or vaccines available to control Ebola outbreaks.
   
   “The important work by Dr. Sullivan and her colleagues shows that it is possible to generate immunity to newly identified species of Ebola virus with a vaccine originally designed to protect against a different species,” says NIAID Director Anthony S. Fauci, M.D. “This finding will guide future vaccine design and may open an avenue for developing a single vaccine that works against both known and emerging Ebola virus species.”
   
   The experimental Ebola vaccine being developed at NIAID has two components, a prime and a boost. The prime consists of a DNA vaccine containing a small piece of genetic material encoding surface proteins from Zaire ebolavirus and Sudan ebolavirus. The boost consists of a weakened cold virus that delivers the Zaire ebolavirus surface protein.
   
   Previously, Dr. Sullivan and her collaborators demonstrated that the prime-boost strategy produces a strong antibody response in monkeys. More importantly, the experimental vaccine induces a robust reaction by the cellular arm of the immune system. The cellular arm includes T cells, which help orchestrate the overall immune response.
   
   “An ideal Ebola vaccine would stimulate broad immunity so that we wouldn’t have to scramble to create entirely new vaccines whenever new virus species are identified,” notes Dr. Sullivan.
   
   However, developing one vaccine to protect against multiple Ebola virus species poses a challenge, she says. To the antibody-producing arm of the immune system, each species looks different. Neutralizing antibodies that recognize one Ebola species cannot readily recognize, or cross-neutralize, the others. T cells, in contrast, can cross-react, even when the target viruses share only small pieces in common.
   
   After the emergence of Bundibugyo ebolavirus (BEBOV) in 2007, Dr. Sullivan’s team decided to revisit the prime-boost vaccine regimen to see if the cellular immunity generated would confer protection against the new virus species.
   
   Four cynomolgus macaques received the DNA prime vaccine. A year later, the animals were boosted with the vector vaccine. Shortly after the boost, the four vaccinated monkeys and four unvaccinated ones
   Researcher working in a biosafety level 4 laboratory
   View larger image
   Credit: U.S. Army Medical Research Institute of Infectious Diseases
   serving as controls were exposed to lethal levels of BEBOV. All the unvaccinated animals became ill, and three died. None of the vaccinated animals showed any sign of illness. Analysis showed that the vaccinated monkeys developed T-cell responses sufficient to prevent or control infection by the novel Ebola virus species, even though the vaccine did not contain material from BEBOV and no antibodies against BEBOV were produced. The animal study was conducted in maximum-level biosafety containment laboratories at U.S. Army Medical Research Institute of Infectious Diseases.
   
   Now the research team is evaluating what parts of the T-cell response were critical to the vaccine’s success against BEBOV. “Once we identify those critical aspects, we can design future vaccines to better elicit that desired immune cell-based activity and perhaps make a single vaccine that protects against all Ebola virus species,” says Dr. Sullivan.
   
   For more information on NIAID research on Ebola and other hemorrhagic fever viruses, visit NIAID's Ebola/Marburg portal. ###
   www.niaid.nih.gov/news/newsreleases/2...
3. MeawandMoo1 26 mei 2010 22:19

   auteur info

   • MeawandMoo1

     Lid sinds: 22 jan 2006

     Laatste bezoek: 28 jul 2024

   • Aanbevelingen

     Ontvangen: 420

     Gegeven: 38

   •    Aantal posts: 459

   quote:

   gocrucellgo schreef:

   Hier zou Flosz hem volgens mij zetten.
   Thursday, May 20, 2010
   
   Experimental Vaccine Protects Monkeys from New Ebola Virus
   

   tnx gocrucellgo en ab.
   
   Ik ben zo vrij om de onderstaande ook te plaatsen:
   
   www.fbo.gov/index?s=opportunity&m...
   
   Solicitation Number:
   M5Q50A032 Notice Type:
   
   Award Notice Contract Award Date:
   November 15, 2009
   
   Contract Award Number:
   V797P-5138B
   
   Contract Award Dollar Amount:
   1,282,040.00
   
   Contractor Awardee:
   CRUCELL VACCINES INC.;4216 PONCE DE LEON BLVD;CORAL GABLES;FL;331461827
   
   Synopsis:
   Added: Nov 10, 2009 12:02 pm
   No Description Provided Point of Contact(s):
   Deborah BukowskiContracting Officer
   (708) 786-5219
4. [verwijderd] 26 mei 2010 23:11

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   gocrucellgo schreef:

   Hier zou Flosz hem volgens mij zetten.
   Thursday, May 20, 2010
   
   Experimental Vaccine Protects Monkeys from New Ebola Virus
   
   New research has found that an experimental Ebola vaccine developed by researchers at the National Institutes of Health protects monkeys against not only the two most lethal Ebola virus species for which it was originally designed, both recognized in 1976, but also against a newer Ebola virus species that was identified in 2007.
   
   Nancy J. Sullivan,
   ...
   The experimental Ebola vaccine being developed at NIAID has two components, a prime and a boost. The prime consists of a DNA vaccine containing a small piece of genetic material encoding surface proteins from Zaire ebolavirus and Sudan ebolavirus. The boost consists of a weakened cold virus that delivers the Zaire ebolavirus surface protein.
   
   Previously, Dr. Sullivan and her collaborators demonstrated that the prime-boost strategy produces a strong antibody response in monkeys. More importantly, the experimental vaccine induces a robust reaction by the cellular arm of the immune system. The cellular arm includes T cells, which help orchestrate the overall immune response.
   ...
   

   IMO een hernieuwde test met 'n prime-boost vaccin met een DNA vaccine van Vical als prime, en een Adenovirus-vector van Crucell als boost.
   Deze combinatie blijkt nu ook tegen nieuwe Ebola/Marburg stammen effectief. Dat is mooi.
   
   Onduidelijk blijft hier of ze voor de boost de oorspronkelijke Ad5, of een nieuwe Ad-vector (Ad35, Ad26?) gebruikt hebben, die Crucell voor het nieuwe ontwikkelprogramma uit 3 october 2008 gebruikt.
   
   Onduidelijk is ook of er nog serieus naar een prime-boost vaccin voor ebola wordt toegewerkt (net als nu het geval lijkt te zijn met Crucell/GSK bij Malaria), of dat Crucell (met Ad-vectoren) of IBT (met z'n vlp's) het allein gaan worden. Is dit onderzoek een wetenschappelijk leukigheidje of een serieuze opmaat naar een prime-boost strategie? Ik vermoed dat zowiezo eerst maar eens een nieuwe phase I voor de nieuwe Crucell Ad-vector wordt afgewacht voordat uberhaupt aan een prime-boost phase I trial wordt begonnen. Zal zo'n vaartje niet lopen...